Status:
COMPLETED
Postpartum HPV Vaccination
Lead Sponsor:
University of Alabama at Birmingham
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
HPV-Related Malignancy
Eligibility:
FEMALE
16-26 years
Phase:
PHASE4
Brief Summary
Human papillomavirus (HPV)-related cancers are on the rise in the United States. Furthermore, greater than 90% of cervical cancer cases are attributable to HPV, and cervical cancer disproportionately ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- postpartum day 0-4 after vaginal or Cesarean delivery at UAB hospital
- Exclusion criteria
- Fetal demise or miscarriage, autoimmune disorder, HIV, Hepatitis B/C, chronic steroid use, preeclampsia, non-English speaking
Exclusion
Key Trial Info
Start Date :
April 29 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2020
Estimated Enrollment :
195 Patients enrolled
Trial Details
Trial ID
NCT03451071
Start Date
April 29 2019
End Date
December 30 2020
Last Update
October 4 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233